First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
J. Clin. Oncol 2024 Feb 21;[EPub Ahead of Print], YY Janjigian, JA Ajani, M Moehler, L Shen, M Garrido, C Gallardo, L Wyrwicz, K Yamaguchi, JM Cleary, E Elimova, M Karamouzis, R Bruges, T Skoczylas, A Bragagnoli, T Liu, M Tehfe, T Zander, R Kowalyszyn, R Pazo-Cid, M Schenker, K Feeny, R Wang, M Lei, C Chen, R Nathani, K ShitaraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.